This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Chugai Pharmaceutical Co., Ltd.
Drug Names(s): CT-081, ED-71, eldecalcitol
Description: ED-71 is an active vitamin D3 derivative.
In ovariectomized rat model for osteoporosis, ED-71 caused an increase bone mass at the lumbar vertebra to a greater extent than 1-hydroxyvitamin D3 (alfacalcidol), while enhancing calcium absorption and decreasing serum parathyroid hormone levels to the same degree as alfacalcidol. ED-71 lowered the biochemical and histological parameters of bone resorption more potently than alfacalcidol, while maintaining bone formation markers.
Deal Structure: ED-71 was discovered by Chugai.
In May 2008, Chugai Pharmaceutical announced that it entered into an agreement with Taisho Pharmaceutical to co-develop and co-market ED-71. Under the agreement, Chugai will co-develop the compound with Taisho and co-market it with Taisho Toyama Pharmaceutical, a subsidiary of Taisho. Chugai will receive an upfront fee and milestone payments from Taisho.
Partners: Taisho Pharmaceutical Co., Ltd. Roche Holding AG
Additional information available to subscribers only: